Literature DB >> 12356275

Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in-vitro screening.

Sven Deferme1, Jan Van Gelder, Patrick Augustijns.   

Abstract

In this study, standardized food extracts were screened for their possible inhibitory effect on the P-glycoprotein (P-gp)-mediated efflux of 3H-ciclosporin A (CsA) using the in-vitro Caco-2 model. CsA is commonly used as a substrate for P-gp-related efflux carriers and is characterized by a polarity in transport, the absorptive transport being much lowerthan the secretorytransport (polarityfactor: PF approximately 7). Of the 68 tested, nine extracts showed a decreased efflux of CsA (< 75% of the reference value) and were retained for further experiments on the bidirectional transport of CsA across Caco-2 monolayers. Results of these experiments showed that strawberry, orange, apricot and mint extract exert an inhibitory effect on intestinal P-gp-related functionality (PF < 4.2). The effect of apricot extract was also studied on the bidirectional transport of talinolol, a specific P-gp substrate; inclusion of 1%, v/v, in the apical compartment of Caco-2 monolayers resulted in a significantly reduced polarity in the transport of talinolol (PF reference = 15.5; PF in the presence of apricot extract = 2.5). This study suggests that co-administration of fruit extracts might be a conceptually safe and useful strategy to enhance the intestinal absorption of P-gp substrates. More research is necessary to characterize the impact of this inhibition on P-gp-related efflux mechanisms in other absorption models (in-vitro and in-vivo) and to identify the compounds that are responsible for this inhibitory effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356275     DOI: 10.1211/002235702320402053

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

Authors:  Prithviraj Bose; Edward B Perkins; Connie Honeycut; Martha D Wellons; Tammy Stefan; James W Jacobberger; Emmanouil Kontopodis; Jan H Beumer; Merrill J Egorin; Chiyo K Imamura; W Douglas Figg; Judith E Karp; Omer N Koc; Brenda W Cooper; Selina M Luger; A Dimitrios Colevas; John D Roberts; Steven Grant
Journal:  Cancer Chemother Pharmacol       Date:  2012-02-15       Impact factor: 3.333

Review 2.  Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Authors:  Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

3.  Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.

Authors:  Han Li; Zhang Yan; Wang Ning; Guo Xiao-Juan; Zang Cai-Hong; Jiang Jin-Hua; Ma Fang; Wang Qing-Duan
Journal:  J Biomed Biotechnol       Date:  2011-06-30

4.  Downregulation of MDR1 gene by cepharanthine hydrochloride is related to the activation of c-Jun/JNK in K562/ADR cells.

Authors:  Li Han; Yafeng Wang; Xiaojuan Guo; Yubing Zhou; Jingmin Zhang; Ning Wang; Jinhua Jiang; Fang Ma; Qingduan Wang
Journal:  Biomed Res Int       Date:  2014-10-16       Impact factor: 3.411

Review 5.  Anticancer Potential and Other Pharmacological Properties of Prunus armeniaca L.: An Updated Overview.

Authors:  Dusanka Kitic; Bojana Miladinovic; Milica Randjelovic; Agnieszka Szopa; Javad Sharifi-Rad; Daniela Calina; Veronique Seidel
Journal:  Plants (Basel)       Date:  2022-07-20

6.  Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals.

Authors:  Pengjun Zhou; Rong Zhang; Ying Wang; Dandan Xu; Li Zhang; Jinhong Qin; Guifeng Su; Yue Feng; Hongce Chen; Siyuan You; Wen Rui; Huizhong Liu; Suhong Chen; Hongyuan Chen; Yifei Wang
Journal:  Oncotarget       Date:  2017-11-27

7.  Generating inhibitors of P-glycoprotein: where to, now?

Authors:  Emily Crowley; Christopher A McDevitt; Richard Callaghan
Journal:  Methods Mol Biol       Date:  2010
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.